$COLPAL Delivers Sales Beat, Nomura Turns More Bullish on Growth Outlook

$COLPAL reported a better-than-expected Q1FY27 performance, with strong revenue growth driven by healthy volume expansion, premium product demand and continued market share gains across its oral care portfolio. Encouraged by the company's resilient execution and improving growth outlook, Nomura maintained its 'Buy' rating and raised its target price to ₹2,550, citing confidence in sustained premiumisation, strong brand investments and healthy margin performance. The brokerage believes Colgate is well positioned to deliver consistent earnings growth despite a competitive FMCG landscape.